14 results about "Anti sense" patented technology

This invention discloses five RNAi molecules targeting the genome of the small cutworm, all of which are double-stranded RNA molecules composed of a sense strand and a complementary antisense strand, wherein the nucleotide sequence of the sense strand is selected from SEQ ID NOs:1-5. The lethality of these RNAi molecules against the small cutworm is all above 80%.

This invention belongs to the field of biomedicine, specifically relating to siRNA targeting the angiopoietin-like protein 3 gene and its applications. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-ended complementary nucleotide sequence; or a sense strand of 19 nucleotides and an antisense strand of 21 nucleotides with overhanging ends. The siRNA of this invention can comprehensively lower blood lipids, and has good lipid-lowering effects on triglycerides and LDL-C, helping to significantly reduce the risk of atherosclerosis and cardiovascular disease.

This application relates to the field of biotechnology, and particularly to Arg1-targeting double-stranded oligonucleotides and their conjugates, pharmaceutical compositions, and their application in pulmonary fibrosis. The Arg1-targeting double-stranded oligonucleotide comprises a sense strand and an antisense strand, wherein the sense strand and antisense strand are at least partially anticomplementary to form a double-stranded region; the nucleotide sequence of the sense strand comprises a sequence differing from the sequence shown in SEQ ID NO.1 by no more than 3 nucleotides, and the nucleotide sequence of the antisense strand comprises a sequence differing from the sequence shown in SEQ ID NO.2 by no more than 3 nucleotides. Using this Arg1-targeting double-stranded oligonucleotide and its conjugates, or pharmaceutical compositions containing it, to reprogram the nucleic acid of M2 macrophages in pulmonary fibrosis can effectively alter their pro-fibrotic functional state.

Provided is an siRNA that inhibits the expression of an RAGE gene, which siRNA comprises a sense strand and an antisense strand. The provided siRNA has good stability and can be used for efficiently and specifically inhibiting the expression of the RAGE gene, thereby providing important clinical value in the treatment of RAGE-related diseases.

This invention belongs to the field of biomedicine, specifically relating to siRNA that inhibits AR gene expression, comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region, and the sense strand or antisense strand consists of 19-25 nucleotides with blunt ends of complementary nucleotide sequences; or the antisense strand consists of 27 nucleotide sequences with overhangs. The siRNA of this invention can maintain long-term efficacy with a single dose, exhibiting good compliance in patients with chronic diseases such as androgenetic alopecia. Furthermore, it has lower off-target toxicity and fewer side effects compared to small molecule chemical drugs and hormone drugs.

Provided are an INHBE gene-targeted double-stranded oligonucleotide, a conjugate, and a composition, which relate to the technical field of nucleic acid drugs. The double-stranded oligonucleotide comprises a sense strand and an antisense strand. The antisense strand is complementary or substantially complementary to the sense strand; the sense strand comprises a nucleotide sequence identical or substantially identical to at least 15 contiguous nucleotides in a sequence of SEQ ID NO: 309, and said substantially identical means that there is no more than three nucleotide differences between the sense strand and the at least 15 contiguous nucleotides in the sequence of SEQ ID NO: 309. The double-stranded oligonucleotide can effectively inhibit the INHBE gene and treat patients suffering from metabolic diseases or metabolic syndrome and related diseases such as diabetes, hypertension and cardiovascular diseases.

Provided herein is a lipid nanoparticle comprising an encapsulated oligonucleotide molecule, wherein the oligonucleotide molecule is single-stranded or double-stranded and has a length of between 5 and 500 nucleotides; and 20 to 70 mol % of a neutral lipid content relative to total lipid present in the lipid nanoparticle, an ionizable lipid; a sterol; and optionally a hydrophilic polymer-lipid conjugate.

This invention belongs to the field of biomedicine, specifically relating to siRNA that inhibits MITF gene expression and its applications. The siRNA comprises a sense strand and an antisense strand, which are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-ended complementary nucleotide sequence, or a 19-nucleotide sense strand and a 21-nucleotide antisense strand with overhanging ends. The siRNA of this invention, bound to C16, provides advantages for transdermal delivery, including high penetration, targeting, rapid uptake, and low immunogenicity. By interfering with MITF mRNA expression, melanin production can be reduced at its source.

This application relates to the field of biotechnology, and particularly to small interfering nucleic acids (SMEAs) targeting TGFβR2 and their applications, and further to conjugates, compositions, pharmaceutical compositions, and methods for inhibiting TGFβR2 in subjects for non-diagnostic and therapeutic purposes. The SMEA comprises a sense strand and an antisense strand; the nucleotide sequences of the sense strand and the antisense strand include sequences differing by no more than 3 nucleotides as shown in SEQ ID NO. 1-70; and the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region. This SMEA targeting TGFβR2 can effectively reduce the transcriptional level of TGFβR2.

Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can affect protein expression level, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and / or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency.

The application discloses siRNA targeting interleukin-24 genes and application thereof in treatment of sepsis, and belongs to the technical field of biological medicine. The nucleotide sequence of the siRNA comprises a sense strand shown in SEQ ID NO. 1 and an antisense strand shown in SEQ ID NO. 2; the 5' end of the sense strand is modified by cholesterol, and the 3' end of the antisense strand is modified by methoxy. It is found through animal experiments that the siRNA can effectively inhibit excessive inflammatory response in a sepsis model and significantly improve the survival rate, thereby providing a brand-new candidate drug and a precise target for treatment of sepsis.

This description refers to antisense oligonucleotides that act on SNCA mRNA (e.g., at an intron-exon junction) in a cell, resulting in reduced expression of the SNCA protein. Reduced SCNA protein expression is beneficial for the treatment of certain medical conditions, such as a neurological disorder.

This invention belongs to the field of biomedicine, specifically relating to small interfering nucleic acids (MIRNAs) that inhibit KHK gene expression and their applications. The MIRNA comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-terminated complementary nucleotide sequence; or it consists of a 19-nucleotide sense strand and a 21-nucleotide antisense strand with overhangs. KHK MIRNAs can highly specifically target KHK gene mRNA, precisely reducing or inhibiting the expression of this enzyme, minimizing the impact on other metabolic pathways, and reducing the risk of side effects.

Provided are siRNA and modified siRNA for inhibiting XDH gene expression and applications thereof, including a sense strand and an antisense strand; the sense strand and / or the antisense strand has a length ranging from 19 to 25 nucleotides, the antisense strand is reverse complementary to a segment on a target gene; the sense strand has a nucleotide sequence as shown in SEQ ID NO: 1-14, and the antisense strand has a nucleotide sequence as shown in SEQ ID NO: 18-31. The siRNA molecules and the modified siRNA molecules have high stability and / or high inhibitory activity. The siRNA molecules conjugated with ligands have high inhibitory activity and stability, good liver targeting and the ability to promote endocytosis, can reduce the influence on other tissues or organs and reduce the amount of siRNA molecules, and can achieve the purposes of reducing toxicity and reducing cost.